CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
PET/CT Imaging +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02609737
NCT02609737N/ACompleted
CompareCT.gov

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center·interventional·Posted Nov 20, 2015·Updated Feb 1, 2022

In Brief

A clinical study evaluating PET/CT Imaging, 68Ga-DOTA-JR11, and 1 other intervention for Neuroendocrine Tumors. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 20, 2015
Enrollment StartNov 13, 2015
Primary CompletionDec 10, 2020
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 10.6 years ago

Interventions

PET/CT Imagingdevice

68Ga-DOTA-JR11radiation

177Lu-DOTA-JR11radiation